3sbio, Inc. · HKEX:1530
3sbio — H1 2024 Earnings Presentation
40 slides from 3sbio's earnings presentation, Aug 23, 2024
Slide 1: 2024 Interim Results Presentation
2024 Interim Results Presentation 23 August, 2024
Slide 2: Disclaimer
Disclaimer This document has been prepared by 3SBio Inc. (the "Company") solely for selected recipients for information purposes only. You must read the terms, conditions, limitations, notifications, restrictions, acknowledgments and representations in the following (collectively, the "Terms") befor
Slide 3: Agenda
Agenda Highlights Business R&D Financial Q&A Overview Review 1 2 3 4 5 3
Slide 4: 01 Highlights
01 Highlights
Slide 5: 2024 Interim Results Abstract
2024 Interim Results Abstract Bn 4.4 Net Profit Attributable Bn 3.8 to Owners of the 1.10 1.11 Revenue 04 Parent Adjusted for Non-Operating Items1 YOY 16.0% YOY 1.5% 2023H1 2024H1 2023H1 2024H1 Bn Gross 3.8 1.7 Bn profit 3.2 EBITDA2 1.4 YOY 18.6% Gross profit ratio 86.5% YOY 17.0% 2023H1 2024H1 2023
Slide 6: 2024 Interim Highlights
2024 Interim Highlights • SSS06: NDA accepted for review in CKD anemia Shareholder Returns • TPIAO：Ph III study in CLDT met endpoints • Winlevi ® ：Ph III bridging trial in 12 years old+ the acne • Dividends and repurchase amount totaled 860mn HKD, accounting for over vulgaris is enrolling patients 4
Slide 7: 02 Business Overview
02 Business Overview
Slide 8: Biopharmaceuticals
8 Biopharmaceuticals
Slide 9: TPIAO- Global Exclusive Commercialized rhTPO
TPIAO- Global Exclusive Commercialized rhTPO Revenue of TPIAO, 2024H1 Top 1 market share 1 66% 1 market share in terms of sales, still tops the first position in rhTPO products RMB Mn YOY：22.6% 66.2% 4,205 3,397 3,080 2,476 2,019 2021 2022 2023 2023H1 2024H1 TPIAO Class A（Interleukin-11） Class B（Ora
Slide 10: TPIAO- Improving Patients Coverage
TPIAO- Improving Patients Coverage Chemotherapy Cancer therapy induced Chronic liver Primary immune Got SIT，HRT Expert Myelogenous induced thrombocytopenia（CTIT）got Pediatric disease related acute thrombocytopenia thrombocytopenia Grade A recommendation in Consensus preferred thrombocytopenia （ITP）
Slide 11: TPIAO- Improving Clinical Recognition
TPIAO- Improving Clinical Recognition Liver Diseases March, 2024 • Several studies of rhTPO showed in APASL, shared academic APASL achievements in acute liver failure, acute-on-chronicliver failure The Annual Meeting of the Asian Pacific Association for the Study of the Liver (ACLF), liver cancer ab
Slide 12: rhEPO- EPIAO & SEPO
rhEPO- EPIAO & SEPO Revenue of rhEPO, 2024H1 TOP 1 Market share 1 Two brands dominate 43%1 market share, preside Top 1 position in terms of EPO market share RMB Mn YOY：11.3% • EPIAO® quality standard is consistent with EU Pharmacopeia • Treatment guidelines2 promoted standardized treatment, penetrat
Slide 13: Yisaipu- Explore to Reform
Yisaipu- Explore to Reform Revenue of Yisaipu, 2024H1 Market penetration rate improved RMB Mn • Enhance hospitals coverage and related department coverage, prompt market YOY：9.5% penetration Expand new formulation • Pre-filled injection got approval and marketed in May 2023 789 565 512 Persistent fo
Slide 14: Cipterbin- Provide More Choice for Patients
Cipterbin- Provide More Choice for Patients Revenue of Cipterbin, 2024H1 HER2-positive advanced breast cancer H treatment Grade I recommendations Grade I recommendations: (1) THP1 (IA); (2) TXH2 (2A) RMB Mn --Anti-HER2 mAb (H), including commercialized Trastuzumab, biosimilars, Inetetamab YOY：48.9%
Slide 15: Dermatology
1 5 Dermatology
Slide 16: Mandi – Effective & Reliable Hair Growth Drug
Mandi – Effective & Reliable Hair Growth Drug Revenue of Mandi, 2024H1 • Mandi (5% minoxidil) got the highest endorsement level of recommendation in female androgenetic alopecia (FAGA) • Mandi ranked No.1 among “Dermatology chemical drugs” in 2023 Chinese OTC list RMB Mn YOY：10.0% • Upgrade digital
Slide 17: Mandi- Build Product Matrix, Expand Brand Value
Mandi- Build Product Matrix, Expand Brand Value 1st Generation 2nd Generation Daily Chemical Mandi Tincture Mandi Foam products • Mandi (60mL, 90mL) • Mandi for Female (30mL) • Approved with OTC in Jan 2024; • Mandi “Stand on” Shampoo, conditioner • Innovative technology, fill the gap for skin sensi
Slide 18: New Choice for Teenagers in Acne- Winlevi
New Choice for Teenagers in Acne- Winlevi® WS204 Clascoterone cream Acne vulgaris in 12 years and older 1st new mechanism of action in acne approved by the FDA in 40 years Bridging Trial Phase III • Approved by FDA in Clinical trial shows: November 20211 Winlevi® could reduce the Face domestic emerg
Slide 19: Weight Management Broad Market- Semaglutide
Face Weight Management Broad Market- Semaglutide Chinese number of obese people Forecast of Chinese weight Overweight/obesity rate among loss drug market size1 (Est. 2030): adult Chinese residents >50% 329 mn 1 2020 2021E 2022E 2023E 2024E 2025E 2026E 2027E 2028E 2029E 2030E Semaglutide: Globally re
Slide 20: 03 R&D
a) 0 o o ro)
Slide 21: R&D Pipeline
R&D Pipeline Therapeutic Area Candidates Pre-clinical IND Ph I Ph II Ph III NDA 2 Pre-clinical SSS06 Long-acting rhEPO NDA RD01 Long-acting rhEPO Nephrology TRK-820 Remitch CLD pruritus SSS17 HIF inhibitor TPO-106 CLDT 6 IND& Phase I 304R anti-CD20 Ab CS1003 anti-PD1 Ab Licensed product in Mainland
Slide 22: Key Candidates — Nephrology
Key Candidates — Nephrology SSS06 Glycosylation sites • Extend half-life, dosing at longer intervals, match modified EPO treatment cycles of chemotherapy patents SSS06 NuPIAO（rESA） CKD anemia • NDA accepted for review CIA NDA accepted for review 10% Penetration rate • Rank No.2 among domestic peers
Slide 23: Key Candidates — Hematology / Oncology
Key Candidates — Hematology / Oncology Explore New Indication TPIAO：Recommended in the treatment of HRT in the “Chinese expert consensus on the clinical management of hepatopathy-related thrombocytopenia” TPO-106 Cipterbin: explore applications in Her2- positive breast cancer neoadjuvant, cover more
Slide 24: Key Candidates — Autoimmune
Key Candidates — Autoimmune Focus on broad Chinese autoimmune market LN: lupus nephritis 0.6 Mn number of patients IBD: inflammatory bowel disease LN 0.6 0.6 SLE: systemic lupus erythematosus IBD 0.5 0.7 PN: prurigo nodularis Dermatology 1.2 AS: ankylosing spondylitis Rheumatism 1.0 PsO：psoriasis SL
Slide 25: Key Candidates — Autoimmune
Key Candidates — Autoimmune Build the most competitive autoimmune pipeline in China Indication IND Ph I Ph II Ph III NDA Autoimmune pipeline strategy Moderate-to-severe 2024E PsO 608 Indications Product pipeline The new indications include AD, anti-IL-17A Ab coverage of development, CRSwNP, COPD, mo
Slide 26: 608 (anti-IL-17A mAb): Phase III in PsO Completed
608 (anti-IL-17A mAb): Phase III in PsO Completed Phase III study data in PsO unblinds: met primary endpoints and all secondary endpoints Primary endpoints Key secondary endpoints Secondary endpoints • The primary efficacy data at 12 weeks were excellent, maintenance with rapid response rate and obv
Slide 27: 611 (anti-IL-4R mAb): Phase II in CRSwNP Completed
611 (anti-IL-4R mAb): Phase II in CRSwNP Completed Phase II study in CRSwNP shows significant efficacy • The W16 data showed that the efficacy of all 611 Note: 611 shows W16 data, Dupilumab shows W24 data doses (Q2W and Q4W) was clear and significantly 2.5 2.11 Changes from baseline better than that
Slide 28: Early R&D Layout - Multiple Mature New Drug Development Platforms
Early R&D Layout - Multiple Mature New Drug Development Platforms, Multi-dimensional Screening and Evaluation of Druggability BsAb & Multispecific Pre-clinical Animal Drug A comprehensive research, Ab Platform 5 Effect Platform production and marketing • Convenient, fast, costs-controllable, on- mat
Slide 29: SSGJ-626: 2nd Generation BDCA2 mAb with BIC Potential
SSGJ-626: 2nd Generation BDCA2 mAb with BIC Potential SSGJ-626 Huge Marketing Potential Through inhibiting plasmacytoid dendritic cell Mechanism (pDC), the secretion of IFNα was inhibited. Thus regulating the activity of a range of immune cells Strong BDCA2 affinity (KD: 2.48E-11) Very high Degree o
Slide 30: Key Candidates Outlook
Key Candidates Outlook Est. NDA 2024E 2025E 2026E 2027E~ Time: Hematology/ TPIAO CS1003 (PD-1 Ab) Oncology CLDT Advanced HCC Semaglutide Winlevi ® Dermatology 12 years+ acne vulgaris injection Weight management 608 (IL-17 Ab) 613 (IL-1β Ab) 611 (IL-4R Ab） 610 (IL-5 Ab） Autoimmnue Moderate-to-severe
Slide 31: 04 Financial Review
04 Financial Review
Slide 32: Financial Analysis
Financial Analysis Net Profit Attributable to Revenue Gross Profit Net Profit Attributable to Parent Owners of the Parent Adjusted for Non-Operating Items 16.0 % YOY 18.6 % YOY 11.1% YOY 1.5 % YOY Bn Bn Bn Bn Gross profit ratio: 86.5% 7.8 6.9 6.6 1.92 1.95 6.4 5.7 1.73 5.3 1.65 1.66 1.55 4.4 3.8 3.8
Slide 33: R&D Costs Ratio Improved
R&D Costs Ratio Improved Selling and Distribution Comprehensive Finance R&D Costs Administrative Expenses Expenses Costs Mn Mn Mn Mn R&D Costs 1,594 476 1,375 • Semaglutide BD deal • BsAb etc. R&D promotion 214 307 59 • Early-stage target develop 201 23 Comprehensive Finance Costs Ratio decreased 20
Slide 34: Obtained IFC Long-term Loan Credit
Obtained IFC Long-tern Loan Credit Obtained International Finance Corporation (IFC) granting ＄ 200 mn equivalents long-term low-interest loan credit Further optimized the company's Supported by IFC's The first partner of cash flow and international It is also an IFC in the financing resources to hel
Slide 35: Asset Structure Optimized
Asset Structure Optimized 2024H1 2023 Total Assets 23.6 Bn 23.6 Bn Net Assets Gearing Ratio1 Net Assets 16.5 Bn 16.5 Bn 29.4% 29.3% Debt Asset Ratio 30% 30% 25.0% RMB Bn 13.1% 9.6% ROE2 Improved to 13.1% 16.9 16.5 15.4 2023 2024H1 10 2022 2023 2024H1 1. Gearing ratio = (Long-term& short term liabili
Slide 36: Abundant Cash Asset Reserves
Abundant Cash Asset Reserves Operating Net Inflow Financial Resource 1.1 Bn 7.9 Bn RMB Bn RMB Bn 8.2 7.9 7.4 2.1 2.1 1.6 5.0 4.5 1.2 1.1 2021 2022 2023 2023H1 2024H1 2020 2021 2022 2023 2024H1 36
Slide 37: Our Future BD Strategy
Our Future BD Strategy Sufficient Financial Resource Nearly RMB 8 bn available License-Out Comprehensive Facilities 6 manufacturing plants with 100KL+ Over RMB 2 bn operating cash net cost-effective manufacturing capabilities, inflow annually covering small molecule, large • Promote the innovative p
Slide 38: Advancing ESG Governance
Advancing ESG Governance • Take social responsibilities , devote to public welfare actively • Support “Ankylosing Spondylitis Healthy Village Program”, Aided and treated cumulative thousands of patients in AS, cancer, dialysis etc. • ESG governance retained the AA rating by MSCI, exceeding 84% biote
Slide 39: Q&A
05 Q&A
Slide 40: THANKS
THANKS 3SBio Inc. (1530.HK) Investor Relations ir@3sbio.com 珍 爱 生 命 · 关 注 生 存 · 创 造 生 活 CHERISH LIFE CARE FOR LIFE CREATE LIFE